OncoGenex To Present OGX-427 Data At ASCO 2012 Genitourinary Cancers Symposium

Maybe we are about to have another new treatment for advanced prostate cancer that will earn the coveted descriptor, “ON THE HORIZON.” OncoGenex Pharmaceuticals Inc. (OGXI) has said that they will be presenting preliminary data from their phase 2 trials evaluating their investigational compound OGX-427, in prostate and bladder cancer. The data will be presented at the American Society of Clinical Oncology ( ASCO) 2012 Genitourinary Cancers Symposium which will be held on February 2-4, in San Francisco. OGX-427 is a novel compound designed to reduce levels of Heat Shock Protein 27 (Hsp27) - a cell-survival protein expressed in many [...]